Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120626 · ClinicalTrials.gov registry record · Phase 2
Randomized Controlled Study of Donepezil in Fragile X Syndrome
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT01120626: Completed Phase 2 study, sponsored by Stanford University.
NCT01120626 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01120626, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Fragile X syndrome (FraX) is the most common known heritable cause of human intellectual disability. Though recent research has revealed much about the genetic and neurobiological bases of FraX, knowledge about specific and effective treatments for affected individuals is lacking. Based on information from both human and animal studies, one cause of intellectual disability in FraX may be related to deficits in a particular brain neurotransmitter system (the "cholinergic" system). Thus, the investigators propose to use a specific medication, donepezil, to augment cholinergic system in adolescents affected by FraX. If found to be effective, the knowledge generated by this research may also be relevant to other developmental disorders that share common disease pathways with FraX.
Interventions
- DRUG sugar pill
- DRUG donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01120626
The ClinicalTrials.gov registry entry for NCT01120626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sugar pill is the first listed.
NCT01120626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01120626 about?
NCT01120626 is a clinical study titled "Randomized Controlled Study of Donepezil in Fragile X Syndrome". Fragile X syndrome (FraX) is the most common known heritable cause of human intellectual disability. Though recent research has revealed much about the genetic and neurobiological bases of FraX, knowledge about specific and effective treatments for affected individuals is lacking. Based on informati...
What is the current status of trial NCT01120626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2009-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01120626?
The interventions under investigation include: sugar pill (DRUG), donepezil (DRUG).
Who is sponsoring clinical trial NCT01120626?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.